Matthew Fraser

US Patent:

7115606, Oct 3, 2006

Filed:

Jun 7, 2004

Appl. No.:

10/863770

Inventors:

Steven B. Landau - Wellesley MA, US
Cheryl L. Miller - Natick MA, US
Matthew O. Fraser - Apex NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A61K 31/496

US Classification:

514249

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

20040248979, Dec 9, 2004

Filed:

Jun 3, 2004

Appl. No.:

10/859922

Inventors:

Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Matthew Fraser - Apex NC, US

Assignee:

DYNOGEN PHARMACEUTICALS, INC. - BOSTON MA

International Classification:

A61K031/195
A61K031/137

US Classification:

514/561000, 514/650000

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis comprising coadministering to said subject a first amount of an subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount. The coadministration of a first amount of an subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative can result in an enhanced or synergistic therapeutic effect, wherein the combined effect is greater than the additive effect resulting from separate administration of the first amount of the subunit calcium channel ligand and the second amount of the substituted aminomethyl-phenyl-cyclohexane derivative.

US Patent:

20050020577, Jan 27, 2005

Filed:

Jun 7, 2004

Appl. No.:

10/863771

Inventors:

Steven Landau - Wellesley MA, US
Cheryl Miller - Natick MA, US
Matthew Fraser - Apex NC, US

International Classification:

A61K031/551
A61K031/519

US Classification:

514218000, 514252160, 514260100

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

20050272719, Dec 8, 2005

Filed:

May 4, 2005

Appl. No.:

11/122940

Inventors:

Steven Landau - Wellesley MA, US
Cheryl Miller - Natick MA, US
Matthew Fraser - Apex NC, US

International Classification:

A61K031/519
A61K031/551

US Classification:

514218000, 514252160, 514260100

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

20050282799, Dec 22, 2005

Filed:

May 6, 2005

Appl. No.:

11/124580

Inventors:

Steven Landau - Wellesley MA, US
Cheryl Miller - Natick MA, US
Matthew Fraser - Apex NC, US

International Classification:

A61K031/551
A61K031/519

US Classification:

514218000, 514260100, 514252160

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

US Patent:

6846823, Jan 25, 2005

Filed:

Apr 2, 2004

Appl. No.:

10/817332

Inventors:

Steven B. Landau - Wellesley MA, US
Cheryl L. Miller - Natick MA, US
Matthew O. Fraser - Apex NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A01N 4354

US Classification:

514249

Abstract:

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.